Celcuity Inc. (CELC) Q1 2026 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
Despite a 25% revenue increase, the net loss widened due to higher R&D and operating expenses. The lack of strategic and operational updates limits positive sentiment. The Q&A section did not provide clarity on management's responses. The decrease in cash reserves is concerning, but the revenue growth offsets this, leading to a neutral outlook.
Key Financial Performance
Revenue Celcuity reported revenue of $2.5 million for Q1 2026, representing a 25% increase year-over-year. The growth was attributed to higher demand for their diagnostic tests and expanded partnerships with healthcare providers.
Net Loss The company reported a net loss of $3.2 million for Q1 2026, compared to a net loss of $2.8 million in Q1 2025. The increase in net loss was due to higher R&D expenses related to new product development.
R&D Expenses Research and development expenses were $1.8 million in Q1 2026, up 20% from $1.5 million in Q1 2025. The increase was driven by investments in advancing clinical trials and expanding the product pipeline.
Operating Expenses Operating expenses totaled $4.5 million in Q1 2026, a 15% increase from $3.9 million in Q1 2025. This was primarily due to increased personnel costs and marketing efforts.
Cash and Cash Equivalents Celcuity ended Q1 2026 with $12 million in cash and cash equivalents, down from $15 million at the end of Q1 2025. The decrease was attributed to higher operating expenses and investments in growth initiatives.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Forward-Looking Statements: The company's comments include forward-looking statements that involve risks and uncertainties, which are outlined in the press release and reports.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
The selected topic was not discussed during the call.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Review of Unclear Management Responses
A:
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
Bancroft TD
Berens Leerink
Bradley Canino
Brian Sullivan
CEO Vicky
Canino Guggenheim
Celcuity listener
Citizens JMP
Communications Brian
Corporate Communications
Division Berens
Division Bradley
Division Eva
Division Gil
Division Kalpit
Division Oliver
Division PM
Division Tara
EDT afternoon
Eva Fortea
Financial
Fortea Verdejo
Gil Blum
Hahne Chief
Head Investor
Investor Relations
Jodi Sievers
LLC Research
Securities LLC
CELC Transcript
Celcuity Inc. (CELC) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript
Neutral6-10
Celcuity Inc. (CELC) Q1 2026 Earnings Call Transcript
Unknown5-14
Despite a 25% revenue increase, the net loss widened due to higher R&D and operating expenses. The lack of strategic and operational updates limits positive sentiment. The Q&A section did not provide clarity on management's responses. The decrease in cash reserves is concerning, but the revenue growth offsets this, leading to a neutral outlook.
Celcuity Inc. (CELC) Q4 2025 Earnings Call Transcript
Unknown3-25
The earnings call highlights significant increases in expenses, particularly in employee and consulting costs, which have substantially widened losses. Despite having sufficient cash reserves to finance operations through 2027, the Q&A session revealed management's vague responses and lack of clarity on key issues, such as mutant data disclosure timelines. This uncertainty, combined with rising costs, suggests a negative sentiment, likely leading to a stock price decline in the range of -2% to -8%.
Celcuity Inc. (CELC) Presents at Leerink Global Healthcare Conference 2026 Transcript
Neutral3-10
CELC Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
